Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction

Conditions:   Heart Failure, Diastolic;   Hypertension
Intervention:   Procedure: Renal denervation + medical therapy
Sponsor:   InCor Heart Institute
Recruiting - verified April 2014

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   University of Edinburgh;   AstraZeneca
Not yet recruiting - verified April 2014

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:  
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   North West London Hospitals NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified April 2014

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Not yet recruiting - verified April 2014

PATient Navigator to rEduce Readmissions

Conditions:   Chronic Obstructive Pulmonary Disease;   Heart Failure;   Sickle Cell Disease;   Myocardial Infarction;   Pneumonia;   Vascular Procedures
Interventions:   Behavioral: Hospital usual care;   Behavioral: Patient Navigator;   Behavioral: Peer-led telephone support line
Sponsors:   University of Illinois at Chicago;   Patient-Centered Outcomes Research Institute (PCORI);   University of Illinois at Urbana-Champaign;   Society of Hospital Medicine;   COPD Foundation;   University of Kentucky;   Mended Hearts;   American Heart Association;   Sickle Cell Disease Association of Illinois;   AcademyHealth;   The National Association of Social Workers Foundation;   Respiratory Health Association of Metropolitan Chicago;   University of Illinois Sickle Cell Patient Council;   National Jewish Health;   Olmsted Medical Center;   Baystate Medical Center;   Department of Veterans Affairs
Not yet recruiting - verified April 2014

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2014

Study of the Impact of Dairy Fat on Cardiovascular Health.

Condition:   Metabolic Syndrome
Interventions:   Other: Cheese diet;   Other: Butter diet;   Other: CHO diet;   Other: MUFA diet;   Other: PUFA diet
Sponsors:   Laval University;   Agriculture and Agri-Food Canada;   Dairy Farmers of Canada
Not yet recruiting - verified April 2014

The Healthy Heart Study

Condition:   Cardiac Rehabilitation
Interventions:   Behavioral: Home-based cardiac rehabilitation;   Behavioral: Center-based cardiac rehabilitation
Sponsor:   University of California, San Francisco
Enrolling by invitation - verified April 2014

Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults

Condition:   Coronary Artery Bypass Grafting (CABG) Surgery
Interventions:   Behavioral: Motivational Interviewing (MI;   Behavioral: volitional intervention;   Behavioral: Routine discharge counseling
Sponsor:   Qazvin University Of Medical Sciences
Recruiting - verified April 2014

Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography

Conditions:   Non STEMI;   Unstable Angina
Intervention:   Drug: CXM-2043
Sponsor:   Ischemix, LLC
Not yet recruiting - verified April 2014

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

Condition:   Congestive Heart Failure
Intervention:   Device: Samsung LABGEO IVD-A20 CHF Test
Sponsors:   Samsung Electronics;   Nexus-Dx
Recruiting - verified April 2014

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified April 2014

Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)

Conditions:   PRU(Platelet Reactivity Unit);   APT(Antiplatelet Therapy);   HOTPR(High on Treat Platelet Reactivity)
Intervention:   Drug: clopidogrel, ticagrelor, cilostazole
Sponsor:   Taipei City Hospital
Recruiting - verified April 2014

The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Microcirculation;   Vascular Resistance
Intervention:   Drug: trimetazidine
Sponsor:   Clinical Hospital Center Zemun
Recruiting - verified April 2014

Detecting and Treating High Blood Pressure in Aboriginal Population and Low and Middle Income Countries

Conditions:   Hypertension;   Cardiovascular Disease;   Diabetes
Intervention:   Other: SMS text messaging
Sponsors:   Sunnybrook Health Sciences Centre;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2014

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   Immunodeficiency Virus, Human
Interventions:   Drug: Aspirin 81 mg table;   Drug: Atorvastatin 40 mg
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2013

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified April 2014

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified April 2014

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

BIOFLOW III Satellite-ELADIS

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   C.E.M. Biotronik, S.A.
Recruiting - verified February 2014

A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

Conditions:   Myocardial Infarction;   Coronary Artery Disease
Intervention:   Drug: Abciximab
Sponsor:   University of Melbourne
Active, not recruiting - verified April 2014

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsors:   Medtronic Bakken Research Center;   Medtronic;   Medtronic Clinical Research Institute
Terminated - verified April 2014

The Evaluation Of PF-04950615 (RN316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Condition:   Clopidogrel
Interventions:   Drug: Clopidogrel;   Drug: Discontinue Clopidogrel
Sponsors:   Mount Sinai School of Medicine;   Doris Duke Charitable Foundation
Recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

ABSORB STEMI: the TROFI II Study

Condition:   Acute ST Segment Elevation Myocardial Infarction
Intervention:   Device: Percutaneous Coronary Intervention
Sponsors:   ECRI bv;   Abbott Vascular;   Terumo Europe N.V.
Recruiting - verified April 2014

BIOFLOW III Asia Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Asia Pacific Pte Ltd
Recruiting - verified February 2014

The Efficacy of Citalopram Treatment in Acute Stroke

Condition:   Stroke
Interventions:   Drug: Citalopram;   Drug: Placebo
Sponsors:   University of Aarhus;   The Danish Council for Independent Research
Recruiting - verified September 2013

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP

Conditions:   Prior Acute Myocardial Infarction;   Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l);   Reduced Left Ventricle Ejection Fraction (<50%);   Symptoms of Heart Failure (NYHA Class II-III)
Interventions:   Other: Cardiopulmonary exercise test;   Other: Echocardiogram
Sponsors:   Virginia Commonwealth University;   Novartis Pharmaceuticals
Active, not recruiting - verified April 2014

BIOFLOW-III Israel Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Israel
Recruiting - verified July 2013

Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels

Conditions:   Spinal Cord Injury;   Tetraplegia;   Quadraplegia;   Low HDL-c;   High LDL-c
Intervention:   Dietary Supplement: Omega-3 supplements
Sponsors:   University of Manitoba;   The Association of Rehabilitation Medicine in Manitoba
Recruiting - verified April 2014

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified April 2014

BIOFLOW-III Hungary Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Hungária Kft.
Recruiting - verified July 2013

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following Hospitalization for Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

BIOFLOW-III Canada Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Canada Inc
Not yet recruiting - verified June 2013

Application for Self-Monitoring of Cardiovascular Risk

Condition:   Coronary Artery Disease Which Requires Percutaneous Coronary Intervention(Balloon and/or Stent Treatment).
Intervention:   Device: Self Monitoring Software Application
Sponsor:   Mayo Clinic
Recruiting - verified April 2014

Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery

Conditions:   High Risk Non-cardiac Surgery;   Death;   Delirium;   Kidney Injury;   Myocardial Infarction;   Respiratory Failure;   Postoperative Infection
Intervention:   Other: Observational study
Sponsors:   University of Manitoba;   Canadian Anesthesia Research Foundation;   University of Manitoba Department of Anesthesia
Not yet recruiting - verified April 2014

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Conditions:   Antiphospholipid Syndrome;   Endothelial Dysfunction;   Hyperuricemia;   Gout;   Metabolic Syndrome
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified April 2014

Effect of CPAP on Postoperative Delirium

Conditions:   Sleep Apnea, Obstructive;   Delirium
Intervention:   Device: CPAP
Sponsor:   Duke University
Recruiting - verified April 2014

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer Pharma AG
Recruiting - verified April 2014

Sleep to Lower Elevated Blood Pressure

Conditions:   Hypertension;   Sleep Disorders;   Insomnia;   Cardiovascular Diseases
Intervention:   Behavioral: Online Sleep Education
Sponsors:   University College Hospital Galway;   Health Research Board, Ireland
Active, not recruiting - verified April 2014

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions:   Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
Sponsor:   NewLink Genetics Corporation
Recruiting - verified April 2014

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified April 2014

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Conditions:   ST Segment Elevation Myocardial Infarction (STEMI);   Allogeneic Mesenchymal Bone Marrow Cells
Intervention:   Biological: Stem cells
Sponsors:   Stemedica Cell Technologies, Inc.;   Mercy Gilbert Medical Center at AZ;   Chandler Regional Medical Center at Chandler AZ;   University of California, San Diego
Recruiting - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.

Conditions:   Chronic Total Occlusion of Coronary Artery;   Coronary Occlusion;   Coronary Artery Disease;   Coronary Artery Restenosis;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Restenosis
Intervention:   Device: Absorb Bioresorbable Vascular Scaffold
Sponsor:   Abbott Vascular
Recruiting - verified April 2014

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

BIOFLOW-III Austria Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik Vertriebs-GmbH
Recruiting - verified April 2013

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Condition:   Myocardial Infarction (MI)
Intervention:  
Sponsor:   Abbott
Active, not recruiting - verified April 2014

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

Condition:   Graft vs Host Disease
Intervention:   Drug: Atorvastatin calcium
Sponsors:   Medical College of Wisconsin;   Mehdi Hamadani;   West Virginia University
Recruiting - verified April 2014

Evaluating New Radiation Techniques for Cardiovascular Imaging

Condition:   Coronary Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2014

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myeldysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia;   Bone Marrow Diseases;   Neutropenia;   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Clofarabine;   Drug: Lenalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   Celgene Corporation
Recruiting - verified March 2014

Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

Condition:   Ventricular Tachycardia
Interventions:   Drug: amiodarone;   Drug: sotalol;   Device: Biosense Webster's NAVI-STAR Thermo-Cool
Sponsors:   Duke University;   Duke Clinical Research Institute
Active, not recruiting - verified January 2014

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2014

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Condition:   Type 2 Diabetes
Interventions:   Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)];   Drug: Insulin glargine, metformin, prandial insulin
Sponsors:   University of Washington;   Eli Lilly and Company;   Sanofi;   Bristol-Myers-Squibb/Astra-Zeneca;   DexCom, Inc.;   Bayer;   Becton, Dickinson and Company;   Medicomp;   University of Texas;   Department of Veterans Affairs;   Biomedical Research Institute of New Mexico
Active, not recruiting - verified April 2014

Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Injection of Cyclosporin;   Drug: Placebo;   Procedure: Echocardiography
Sponsor:   Hospices Civils de Lyon
Active, not recruiting - verified March 2014

Intracoronary Administration of Levosimendan in Cardiac Surgery Patients

Condition:   Myocardial Stunning
Interventions:   Drug: levosimendan;   Drug: Vitamin B 12
Sponsor:   Tampere University Hospital
Recruiting - verified April 2014

Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.

Condition:   Hypercholesterolemia
Intervention:   Dietary Supplement: beetroot juice
Sponsors:   Queen Mary University of London;   British Heart Foundation
Completed - verified April 2014

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified April 2014

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients

Condition:   Bleeding
Interventions:   Drug: Bivalirudin;   Drug: Unfractionated Heparin
Sponsor:   Clinica Mediterranea
Completed - verified April 2014

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Condition:   Myocardial Infarction
Intervention:   Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Sponsors:   Capricor Inc.;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: Pazopanib;   Drug: Other anti-VEGFs
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2014

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

Conditions:   Coronary Artery Disease (CAD);   Chronic Total Occlusion (CTO)
Intervention:   Device: CTO Treatment Device
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

Condition:   End Stage Renal Disease
Intervention:  
Sponsors:   University of Alberta;   Massachusetts General Hospital
Recruiting - verified April 2014

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

Condition:   Cardiovascular Disease, Coronary Artery Disease
Interventions:   Drug: UFH;   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH
Sponsor:   Bayer
Completed - verified April 2014

Liraglutide and Heart Failure in Type 2 Diabetes

Conditions:   Congestive Heart Failure;   Type 2 Diabetes Mellitus
Interventions:   Drug: liraglutide;   Drug: glimepiride;   Drug: Metformin
Sponsors:   Karolinska Institutet;   Thomas Nystrom;   Örebro University, Sweden
Recruiting - verified April 2014

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo;   Procedure: Percutaneous Coronary Intervention (PCI)
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: etanercept
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Artery Disease;   General Anesthetic Drug Allergy;   Coronary Artery Bypass Graft Surgery
Interventions:   Drug: Xenon;   Drug: Sevoflurane;   Drug: Propofol
Sponsors:   Air Liquide Santé International;   Orion Corporation, Orion Pharma
Completed - verified April 2014

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

Conditions:   Angioplasty;   Chronic Coronary Occlusion;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Intervention:   Device: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Congestive Heart Failure;   ST-Elevation Myocardial Infarction
Interventions:   Device: Sodium Alginate and Calcium Gluconate;   Device: Saline Solution
Sponsors:   Bellerophon;   Bellerophon BCM, LLC
Recruiting - verified April 2014

Prevention of Contrast Renal Injury With Different Hydration Strategies

Condition:   Contrast Medium-induced Nephropathy
Interventions:   Other: LVEDP -Based hydration strategy;   Other: Standard hydration
Sponsor:   Kaiser Permanente
Completed - verified April 2014

EXCEL Clinical Trial

Conditions:   Chronic Coronary Occlusion;   Unprotected Left Main Coronary Artery Disease;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Interventions:   Device: Percutaneous Coronary Intervention;   Procedure: CABG
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease

Conditions:   Kawasaki Disease;   Aneurysm, Coronary
Intervention:   Drug: Atorvastatin
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Anticoagulation in Stent Intervention

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid + clopidogrel
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified April 2014

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified April 2014

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Management Practices and the Risk of Infection Following Cardiac Surgery

Conditions:   Cardiac Surgery;   Infection, Postoperative Wound;   Postoperative Wound Infection;   Infections, Nosocomial;   Management Practices
Intervention:  
Sponsors:   Mount Sinai School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   National Institute of Neurological Disorders and Stroke (NINDS)
Completed - verified April 2014

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Scripps Translational Science Institute
Recruiting - verified April 2014

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   The George Institute;   Servier
Completed - verified April 2014

Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation

Conditions:   Mitral Valve Insufficiency;   Coronary Artery Disease
Interventions:   Procedure: Mitral Valve Repair with Annuloplasty;   Procedure: Mitral Valve Replacement
Sponsors:   Mount Sinai School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting - verified April 2014

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Conditions:   Arterial Thromboembolic Events;   Atrial Fibrillation
Interventions:   Drug: Placebo;   Drug: Dalteparin
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified April 2014

Antiepileptic Drugs and Vascular Risk Markers

Condition:   Subarachnoid Hemorrhage
Interventions:   Drug: phenytoin;   Drug: valproate;   Drug: levetiracetam
Sponsor:   Thomas Jefferson University
Terminated - verified April 2014

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2014

Tranexamic Acid in Urologic Surgery

Conditions:   Bleeding;   Prostatectomy
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Università Vita-Salute San Raffaele
Completed - verified July 2010

Dexamethasone for Cardiac Surgery Trial

Conditions:   Systemic Inflammatory Response Syndrome;   Cardiac Diseases;   Postoperative Complications
Intervention:   Drug: Dexamethasone
Sponsor:   UMC Utrecht
Completed - verified April 2014

Nurses' Health Study (Cardiovascular Component)

Conditions:   Cardiovascular Diseases;   Diabetes Mellitus;   Coronary Disease;   Heart Diseases;   Cerebrovascular Accident;   Pulmonary Embolism;   Angina Pectoris;   Myocardial Infarction;   Menopause;   Postmenopause
Intervention:  
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2014

Diagnosis of Pheochromocytoma

Condition:   Pheochromocytoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2014

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Conditions:   Atherosclerosis;   Hypercholesterolemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2014

Get CardioSmart

You're Invited